IRIS
PERUCCA, EMILIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.943
EU - Europa 5.832
AS - Asia 4.534
SA - Sud America 37
AF - Africa 23
OC - Oceania 14
Continente sconosciuto - Info sul continente non disponibili 9
Totale 19.392
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.877
CN - Cina 4.033
IE - Irlanda 1.767
UA - Ucraina 1.356
DE - Germania 685
FI - Finlandia 584
SE - Svezia 436
SG - Singapore 374
GB - Regno Unito 349
IT - Italia 294
FR - Francia 139
RU - Federazione Russa 108
CA - Canada 66
IN - India 44
BE - Belgio 33
JP - Giappone 32
BR - Brasile 28
NL - Olanda 21
PL - Polonia 14
MU - Mauritius 13
SI - Slovenia 12
AU - Australia 11
CZ - Repubblica Ceca 11
IL - Israele 11
EU - Europa 9
CL - Cile 8
TR - Turchia 7
EG - Egitto 6
IR - Iran 6
HK - Hong Kong 5
ES - Italia 4
KR - Corea 4
GR - Grecia 3
LT - Lituania 3
NZ - Nuova Zelanda 3
TH - Thailandia 3
HU - Ungheria 2
ID - Indonesia 2
LV - Lettonia 2
PK - Pakistan 2
SA - Arabia Saudita 2
UG - Uganda 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
CH - Svizzera 1
CY - Cipro 1
DK - Danimarca 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
HR - Croazia 1
IS - Islanda 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
NO - Norvegia 1
NP - Nepal 1
PE - Perù 1
PH - Filippine 1
RO - Romania 1
TW - Taiwan 1
Totale 19.392
Salva come PNG Salva come JPEG
Città #
Chandler 1.861
Dublin 1.767
Jacksonville 1.659
Nanjing 1.223
Boardman 601
Ashburn 519
Nanchang 471
Princeton 448
Lawrence 417
Wilmington 412
Shenyang 355
Hebei 347
Changsha 340
Jiaxing 278
Medford 267
Singapore 259
Beijing 215
Tianjin 204
Hangzhou 185
Ann Arbor 175
Helsinki 153
Woodbridge 126
Milan 97
Fairfield 91
Saint Petersburg 85
Shanghai 84
Norwalk 71
Verona 71
Houston 68
Cambridge 51
Toronto 49
Seattle 42
Los Angeles 38
Chicago 35
New York 34
Brussels 33
Des Moines 31
Kunming 29
Falls Church 27
Pavia 27
Tokyo 27
Council Bluffs 23
Dearborn 23
Pune 22
Zhengzhou 22
Jinan 21
San Francisco 21
Taizhou 20
Guangzhou 18
Piscataway 17
Washington 16
Auburn Hills 14
Dallas 13
Ljubljana 12
Ningbo 12
London 10
Orange 10
Radomsko 10
Tappahannock 10
Changchun 9
Fuzhou 9
Ottawa 9
Brno 8
Berlin 7
Munich 7
Redmond 7
Borås 6
Lanzhou 6
Melbourne 6
Cairo 5
Frankfurt am Main 5
Redwood City 5
São Paulo 5
Biandronno 4
Como 4
Giv‘atayim 4
Gunzenhausen 4
Handan 4
Jerusalem 4
Jinhua 4
Las Vegas 4
Murphysboro 4
Paris 4
Rockville 4
Santa Clara 4
Xian 4
Amsterdam 3
Auckland 3
Canberra 3
Chiari 3
Cologno Monzese 3
Delhi 3
Dortmund 3
Haikou 3
Hefei 3
Kemerovo 3
Limoges 3
Markham 3
Palermo 3
Phoenix 3
Totale 13.754
Salva come PNG Salva come JPEG
Nome #
No proof of a causal relationship between antiepileptic drug treatment and incidence of dementia. Comment on: Use of antiepileptic drugs and dementia risk—An analysis of Finnish health register and German health insurance data 127
Low risk pragmatic trials do not always require participants' informed consent 111
Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbamazepine in healthy women 100
Development and validation of an HPLC-UV detection assay for the determination of rufinamide in human plasma and saliva. 88
Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy. 87
Characteristics of a large population of patients with refractory epilepsy attending tertiary referral centers in Italy. on behalf of the SOPHIE Study Group. 84
A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. 83
A Prospective study on the effects of antiepileptic drugs on the human foetus: The European Registry initiative 82
Alterazioni del campo visivo in soggetti epilettici in trattamento cronico con vigabatrin. 81
Stereoselective determination of vigabatrin enantiomers in human plasma by high performance liquid chromatography using UV detection. 81
Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age 81
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. 79
Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience 78
A simple and rapid HPLC-UV method for the determination of retigabine in human plasma 78
Add-on lamotrigine treatment in children and young adults with severe partial epilepsy: a open, prospective, long-term study 76
Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine sources of variability and preliminary observations on relations with clinical response. 75
A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in human plasma 75
Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry 75
What clinical trial designs have been used to test antiepileptic drugs and do we need to change them? 73
Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and puerperium. 72
A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. 72
A multiparametric investigation of daytime sleepiness and psychomotor functions in epileptic patients treated with phenobarbital and sodium valproate: a comparative controlled study 72
A Double-Blind, Placebo-Controlled Study on the Effect of Vigabatrin on In Vivo Parameters of Hepatic Microsomal Enzyme Induction and on the Kinetics of Steroid Oral Contraceptives in Healthy Female Volunteers 72
Erratum The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: The PuLsE (Open Prospective Randomized Long-term Effectiveness) trial (Epilepsia (2014) 55 (893-900) 72
The remarkable story of valproic acid 72
Choreiform syndrome associated with fluoxetine treatment in a patient with deficient CYP2D6 activity. 72
The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction 71
Pharmacokinetic variability of new antiepileptic drugs at different ages. 70
Effect of active and passive cigarette smoking on CYP1A2-mediated phenacetin disposition in Chinese subjects. 70
The management of refractory idiopathic epilepsies 69
Increased Apparent Oral Clearance of Valproic Acid during Intake of Combined Contraceptive Steroids in Women with Epilepsy 69
Overtreatment in epilepsy: adverse consequences and mechanisms. 68
Role of valproate across the ages. Treatment of epilepsy in the elderly 68
Improving Epilepsy for Life: editorial comment. 67
Addressing overtreatment in patients with refractory epilepsy at a tertiary referral center in Brasil. 67
Seizure control and treatment in pregnancy. Observations from the EURAP Epilepsy Pregnancy Registry 67
Valproic acid after five decades of use in epilepsy: Time to reconsider the indications of a time-honoured drug 67
Therapeutic strategies against epilepsy in Mediterranean countries: a report from an international collaborative survey. 67
The new antiepileptic drugs: Pharmacological and clinical aspects. 66
A PHARMACOLOGICAL AND CLINICAL REVIEW ON TOPIRAMATE, A NEW ANTIEPILEPTIC DRUG, 66
Gender issues in antiepileptic drug treatment 66
Adverse drug interactions in epilepsy 66
Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). 66
Revisiting phenobarbital for epilepsy. 65
Drugs in early clinical development. 65
Omeprazole Does Not Enhance the Metabolism of Phenacetin, a Marker of CYP1A2 Activity, in Healthy Volunteers 65
Concentrations of L-dopa in plasma and plasma ultrafiltrates. 65
Can drug resistance in epilepsy be minimized? Challenging commonly held beliefs. 65
Recent advances in the diagnosis and treatment of epilepsy 64
NICE guidance on newer drugs for epilepsy in adults 64
Influence of aging on serum phenytoin concentrations: A pharmacokinetic analysis based on therapeutic drug monitoring data. 64
Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. 64
Tiagabina: aspetti farmacologici e clonici 63
Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. 63
Cost minimization analysis of antiepileptic drugs in newly diagnosed epilepsy in 12 European countries 63
Overtreatment in epilepsy : How it occurs and how it can be avoided 63
Plasma gabapentin concentrations in children with epilepsy: Influence of age, relationship with dosage, and preliminary observations on correlation with clinical response 63
Novel frontiers in epilepsy treatments: preventing epileptogenesis by targeting inflammation 63
Commentary: Epilepsy is a Global Problem 63
A young woman with recurring seizures. 63
Epilessia nell'anziano:dati dai registri di un centro neurologico. 63
Farmacocinetica delle benzodiazepine. 63
Clinically important drug interactions in epilepsy: Interactions between antiepileptic drugs and other drugs. 63
What can we learn from clinical trials of anticonvulsant drugs in epilepsy? 62
Withdrawing antiepileptic drugs in seizure-free patients: what are the cognitive benefits? 62
Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction 62
Effects of phenytoin on the in vivo kinetics of thiamine and its phosphoesters in rat nervous tissues 62
Offspring of mothers with epilepsy. 61
Assessing risk to benefit ratio in antiepileptic drug therapy 61
The International League Against Epilepsy at the threshold of its second century: year 1. 61
Antiepileptic drug selection for people with HIV/AIDS: Evidence-based guidelines from the ILAE and AAN 61
Acute tolerance to the tremorolytic effect of primidone. 61
Commentary: Why an International Epilepsy Day? 61
The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: The PuLsE (OpenProspective RandomizedLong-termEffectiveness) trial 61
Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders 60
Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation 60
Trial duration and follow-up 60
Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management. 60
Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. 60
When clinical trials make history: Demonstrating efficacy of new antiepileptic drugs as monotherapy. 60
Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments.SOPHIE Study Group. 60
Combination therapy and drug interactions. 59
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. 59
The clinical pharmacokinetics of the newer antiepileptic drugs - Focus on topiramate, zonisamide and tiagabine 59
Daytime sleepiness in healthy university students: A multiparametric study 59
Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. 59
Clinical pharmacokinetics of fluvoxamine. 59
Development and validation of an HPLC-UV assay for the therapeutic monitoring of the new antiepileptic drug perampanel in human plasma 59
Marketed new antiepileptic drugs: are they better than old-generation agents? 58
Patient-tailored antiepileptic drug therapy: Predicting response to antiepileptic drugs 58
Anticonvulsants 58
Pregabalin as Adjunctive Treatment of Partial Seizures: A Viewpoint 58
Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the presence and absence of enzyme induction by carbamazepine. 58
Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects. 58
Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects 58
The disposition of theophylline in patients with lung and breast cancer. 58
THE INFLUENCE OF OLD AGE AND ENZYME INDUCING COMEDICATION ON THE PHARMACOKINETICS OF VALPROIC ACID AT STEADY STATE: A CASE-MATCHED EVALUATION BASED ON THERAPEUTIC DRUG MONITORING DATA. 58
Topiramate: from a drug of last resort to a first-line treatment option. 9th Iranian Congress of Neurology and Clinical Neurophysiology 57
Tiagabine in the treatment of epilepsy. A clinical review with a guide for the prescribing physician. 57
New and forthcoming anti-epileptic drugs. 57
Totale 6.743
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.180
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.180
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020799 0 0 0 0 0 0 13 280 26 337 132 11
2020/20212.400 276 225 79 240 7 323 7 400 78 351 316 98
2021/20221.632 31 5 64 21 20 36 27 101 100 18 275 934
2022/20235.273 641 314 37 471 518 593 0 355 2.110 25 136 73
2023/20241.577 222 281 58 137 170 413 30 107 11 45 60 43
2024/20251.187 141 480 126 178 74 186 2 0 0 0 0 0
Totale 19.759